COMPASS Pathways (CMPS) Competitors $4.05 +0.08 (+2.02%) (As of 05:30 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CMPS vs. CALT, SPRY, SNDX, ANIP, RCKT, BCYC, AVDL, COLL, SEPN, and BCAXShould you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), Syndax Pharmaceuticals (SNDX), ANI Pharmaceuticals (ANIP), Rocket Pharmaceuticals (RCKT), Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), Collegium Pharmaceutical (COLL), Septerna (SEPN), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. COMPASS Pathways vs. Calliditas Therapeutics AB (publ) ARS Pharmaceuticals Syndax Pharmaceuticals ANI Pharmaceuticals Rocket Pharmaceuticals Bicycle Therapeutics Avadel Pharmaceuticals Collegium Pharmaceutical Septerna Bicara Therapeutics COMPASS Pathways (NASDAQ:CMPS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings. Which has more risk & volatility, CMPS or CALT? COMPASS Pathways has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Does the media prefer CMPS or CALT? In the previous week, COMPASS Pathways had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for COMPASS Pathways and 0 mentions for Calliditas Therapeutics AB (publ). COMPASS Pathways' average media sentiment score of 1.53 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that COMPASS Pathways is being referred to more favorably in the media. Company Overall Sentiment COMPASS Pathways Very Positive Calliditas Therapeutics AB (publ) Neutral Is CMPS or CALT more profitable? COMPASS Pathways has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. COMPASS Pathways' return on equity of -63.85% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets COMPASS PathwaysN/A -63.85% -51.97% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Do institutionals & insiders have more ownership in CMPS or CALT? 46.2% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 4.3% of COMPASS Pathways shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer CMPS or CALT? COMPASS Pathways presently has a consensus price target of $33.60, indicating a potential upside of 725.55%. Calliditas Therapeutics AB (publ) has a consensus price target of $39.25, indicating a potential downside of 1.88%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, analysts clearly believe COMPASS Pathways is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable valuation and earnings, CMPS or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than COMPASS Pathways. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOMPASS PathwaysN/AN/A-$118.46M-$2.20-1.85Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the MarketBeat Community prefer CMPS or CALT? COMPASS Pathways received 33 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 80.00% of users gave COMPASS Pathways an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCOMPASS PathwaysOutperform Votes6080.00% Underperform Votes1520.00% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% SummaryCOMPASS Pathways beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks. Ad Weiss RatingsNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Get COMPASS Pathways News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPS vs. The Competition Export to ExcelMetricCOMPASS PathwaysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$278.47M$6.61B$5.16B$9.10BDividend YieldN/A2.99%5.12%4.26%P/E Ratio-1.8510.6387.5117.12Price / SalesN/A194.281,136.45119.65Price / CashN/A57.1643.2337.85Price / Book1.125.104.784.77Net Income-$118.46M$151.83M$120.55M$225.50M7 Day Performance-6.00%-1.19%-1.64%-1.29%1 Month Performance-7.71%-4.73%14.04%0.45%1 Year Performance-53.49%8.89%28.88%15.38% COMPASS Pathways Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPSCOMPASS Pathways2.8388 of 5 stars$4.05+2.0%$33.60+729.6%-54.6%$277.11MN/A-1.84120Positive NewsCALTCalliditas Therapeutics AB (publ)0.0652 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SPRYARS Pharmaceuticals3.1382 of 5 stars$12.26+3.0%$24.00+95.8%+116.7%$1.19B$30,000.00-23.3390News CoverageSNDXSyndax Pharmaceuticals3.9757 of 5 stars$13.76-1.2%$37.64+173.5%-37.5%$1.17B$16M-3.84110ANIPANI Pharmaceuticals4.8421 of 5 stars$55.69-1.6%$77.71+39.5%-0.1%$1.17B$555.46M-102.89642Positive NewsRCKTRocket Pharmaceuticals4.851 of 5 stars$11.94-0.7%$51.00+327.1%-61.6%$1.09BN/A-4.37240BCYCBicycle Therapeutics3.6138 of 5 stars$15.46+11.9%$36.00+132.9%-21.4%$1.07B$26.98M-4.56240High Trading VolumeAVDLAvadel Pharmaceuticals2.6912 of 5 stars$10.93+5.2%$24.43+123.5%-25.3%$1.05B$138.16M-13.15154Positive NewsCOLLCollegium Pharmaceutical3.94 of 5 stars$30.57+1.6%$42.60+39.4%-1.2%$985.88M$599.25M12.97210News CoverageSEPNSepterna2.023 of 5 stars$22.05-1.5%$43.67+98.0%N/A$979.02MN/A0.00N/ANews CoverageBCAXBicara TherapeuticsN/A$17.57+0.4%$43.00+144.7%N/A$956.09MN/A0.0032 Related Companies and Tools Related Companies CALT Competitors SPRY Competitors SNDX Competitors ANIP Competitors RCKT Competitors BCYC Competitors AVDL Competitors COLL Competitors SEPN Competitors BCAX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMPS) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPS Stock Alerts